Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
about
Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patientsMolecular-targeted therapy for advanced gastric cancerTreatment of gastric cancerCritical appraisal of trastuzumab in treatment of advanced stomach cancerThe use of lentinan for treating gastric cancerMolecular-targeted first-line therapy for advanced gastric cancerMolecular mechanisms of peritoneal dissemination in gastric cancerNew advances in targeted gastric cancer treatmentGenomic diversity of colorectal cancer: Changing landscape and emerging targetsThe efficacy and potential predictive factors of PD-1/PD-L1 blockades in epithelial carcinoma patients: a systematic review and meta analysisExploring the role of molecular biomarkers as a potential weapon against gastric cancer: A review of the literatureHER2 heterogeneity in gastric/gastroesophageal cancers: From benchside to practiceClinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-esophageal junction adenocarcinomaGastric biomarkers: a global reviewCurrent and emerging therapies in unresectable and recurrent gastric cancerEmerging molecular classifications and therapeutic implications for gastric cancerRecent updates of precision therapy for gastric cancer: Towards optimal tailored managementHER2 testing in gastric cancer: An updateTaxanes in the Treatment of Advanced Gastric CancerGenomic alterations and molecular subtypes of gastric cancers in AsiansEmerging therapeutic targets in esophageal adenocarcinomaRecent developments and innovations in gastric cancerRecent developments in receptor tyrosine kinases targeted anticancer therapyPerioperative and Palliative Chemotherapy for Esophageal CancerMolecular alterations in gastric cancer with special reference to the early-onset subtypeFibroblast growth factor receptor signaling as therapeutic targets in gastric cancerAdvanced gastric cancer: Current treatment landscape and future perspectivesNovel targets in the treatment of advanced gastric cancer: a perspective reviewClinical modalities for management of gastric cancer hepatic metastasisCurrent Molecular Targeted Therapy in Advanced Gastric Cancer: A Comprehensive Review of Therapeutic Mechanism, Clinical Trials, and Practical ApplicationCytoreductive surgery and hyperthermic intraperitoneal chemotherapy for gastric cancer and other less common disease histologies: is it time?Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potentialSystemic therapy of non-colorectal gastrointestinal malignancies in the elderlyChemotherapy in Elderly Patients with Gastric CancerTargeted therapy for advanced gastric cancer: A review of current status and future prospectsNeo-adjuvant chemo(radio)therapy in gastric cancer: Current status and future perspectivesGenomic and epigenomic heterogeneity in molecular subtypes of gastric cancerChanging strategies for target therapy in gastric cancerPersonalized medicine in gastric cancer: Where are we and where are we going?Advanced gastric cancer: What we know and what we still have to learn
P2860
Q21261244-86A88074-C4FD-4D9F-B503-0F2240AA064AQ24187006-D538D241-7CDB-4479-B055-0BB33E2DF6A9Q24602875-3496EF28-A8E8-4C66-A50C-928982E990D3Q24604411-5698076B-B1B3-4A48-9881-3E97CDA9D19DQ24619416-E2D563BA-B10D-429F-A49D-9316AF0A68FCQ26471049-C991C488-22BC-4D5F-A930-E142B0412C31Q26738538-63AF0D4C-07B2-4A4D-9ABE-DCA50F084643Q26738548-943D514F-1241-438C-BC3D-337E246FBEA0Q26739052-73A182D2-6260-4590-BD2E-5C66EA09CFCCQ26740280-9F74D470-0B2D-4286-94C7-E6E226869088Q26741242-4970BA2E-5573-4293-B150-CC152D3878D6Q26741253-70D7A295-B569-402C-828B-17823055619EQ26741530-2725A800-5397-47B3-946E-AF2B0288837CQ26741859-CC5CAF9A-C9CA-43AB-BBFB-AD20CB04AEA5Q26745453-DF7B6462-ACB1-4E2B-8778-88E5096CB19FQ26745525-0A8C71E9-68C8-4986-B2E4-5261B88860C6Q26746246-828B12C0-4ABE-42DD-90C1-64C199F48E33Q26746253-3E4FA1E5-BAF1-4069-AA8A-8959B5089F08Q26747708-DB358D18-93DD-483C-8574-36CC761341FAQ26751062-D614B988-F41D-4102-81EA-362E3EA64967Q26751209-FFCDE1EF-35A8-4887-9F59-6780F3408EE3Q26751327-1EDD0801-F6E4-4F8D-9EB0-432D46772AF4Q26751331-659A1591-0F5B-4755-881F-83B544B3FA7BQ26753865-F989A218-F2A5-4387-B77E-E669047E667AQ26764919-4CE55E5B-68F4-47AB-95B7-AD95305A9C3FQ26764932-789F45A6-9C88-4E4A-9B75-D8993B74F8E7Q26764934-2DBE9C89-D76F-4E21-B13C-36FDB4E7A42FQ26765208-41D533AE-B72A-4BCA-A177-0D7A1E4BCA24Q26765314-66E981D8-14AD-45F3-8991-C8D16A9D407FQ26765941-1301FE23-6851-4118-887A-B8224AC57AD7Q26768312-636FDDF3-4DB3-444F-9160-C236B386BE5DQ26769884-E4C0F195-0ABB-4396-ACC8-9F9E4A19933DQ26771399-54C7D393-168C-411C-9040-18A5B6DE4143Q26771424-F313463E-A75D-48DD-B038-CA59087465B3Q26774138-087AC19F-579C-456F-8152-6BF8EF36B81CQ26774283-3E889D91-18AA-487A-A72B-996117DF6A3CQ26774509-6EC37930-36DE-4A3E-B525-25E0E499CF21Q26774513-A4C1A5AD-1763-4974-A4C8-E023DA92D02BQ26774521-07E18DEB-53A5-442F-9639-4A6233A5A9E6Q26774528-AAC91F2B-4953-4180-84DC-B4427BB8C448
P2860
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Trastuzumab in combination wit ...... , randomised controlled trial.
@ast
Trastuzumab in combination wit ...... , randomised controlled trial.
@en
Trastuzumab in combination wit ...... , randomised controlled trial.
@nl
type
label
Trastuzumab in combination wit ...... , randomised controlled trial.
@ast
Trastuzumab in combination wit ...... , randomised controlled trial.
@en
Trastuzumab in combination wit ...... , randomised controlled trial.
@nl
prefLabel
Trastuzumab in combination wit ...... , randomised controlled trial.
@ast
Trastuzumab in combination wit ...... , randomised controlled trial.
@en
Trastuzumab in combination wit ...... , randomised controlled trial.
@nl
P2093
P3181
P1433
P1476
Trastuzumab in combination wit ...... , randomised controlled trial.
@en
P2093
Akira Sawaki
Andrea Feyereislova
Atsushi Ohtsu
Evgeny Kulikov
Florian Lordick
Giuseppe Aprile
Hyun C Chung
Josef Rüschoff
Julie Hill
P304
P3181
P356
10.1016/S0140-6736(10)61121-X
P407
P577
2010-08-28T00:00:00Z